mRNA platforms & LNP delivery

01Overview and value chain

Markers: [EC: ATMP Regulation (EC No 1394/2007) | OECD: Bio-Pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)]

mRNA platforms with lipid-nanoparticle (LNP) delivery are a revolutionary biopharma paradigm: synthetic messenger RNA carries the genetic instruction straight into the cytoplasm, turning the cell into a bioreactor for therapeutic proteins, antigens or personalised neoantigens. Because “naked” mRNA is unstable, LNPs of 60–100 nm encapsulate it, enabling endocytosis and endosomal escape. An LNP has four lipids: ionizable (neutral at pH 7.4, positive in the endosome), PEG-lipid, phospholipid and cholesterol. After the COVID-19 breakthrough (Comirnaty, Spikevax), the sector is scaling into cancer vaccines and replacement protein therapy.

Key directions of mRNA platforms:

1. Infectious vaccines (Infectious Vaccines): COVID-19, RSV, influenza — platform re-use of the LNP shell.
2. Personalised cancer vaccines (Personalised Cancer Vaccines): up to 34 neoantigens per patient (mRNA-4157).
3. Self-amplifying RNA (Self-Amplifying RNA): saRNA needs lower doses (ARCT-154).
4. In-vivo protein expression & in-vivo CAR (In-Vivo Protein Expression): rare-disease therapy and CAR-T without ex-vivo.

Sectoral value chain

[DNA template] ──> [IVT transcription] ──> [mRNA purification] ──> [LNP assembly]
                          │
                  (cell-free synthesis)
                          │
                          ▼
[drug product] <─── [fill/lyophilisation] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• Nucleotide modification (Nucleotide Modification): N1-methylpseudouridine (m1Ψ) — 2023 Nobel — dampens innate immunity.
• Microfluidic mixing (Microfluidic Mixing): herringbone mixers give PDI <0.1 and encapsulation >90%.
• Co-transcriptional capping (Co-transcriptional Capping): CleanCap® — >95% Cap-1 in one step.

02US

The US leads on mRNA capitalisation, patents and clinical scale-up, with mature CDMO infrastructure.

Moderna leadership, CDMO infrastructure, FDA platform guidance

• Moderna: mRNA-4157 (V940) + Keytruda — phase III melanoma recurrence reduction.
• CDMO + LNP components: TriLink (CleanCap), Catalent, Lonza — full upstream capacity.
• FDA: platform regulatory guidance — re-use of LNP-shell safety data across candidates.

03CN

China treats mRNA as a biotech-sovereignty domain, localising the whole lipid and enzyme chain.

Walvax/Abogen, raw-material localisation, Suzhou BioBAY hub

• Abogen/Walvax: AWcorna and domestic mRNA vaccines; LNPs stable at +2–8°C.
• Localisation: Yeasen — m1Ψ, T7 polymerase, ionizable lipids (SM-102/ALC-0315 analogues).
• BioBAY (Suzhou): China’s main mRNA cluster (hepatitis B, liver cancer, metabolic diseases).

04EU

The EU is the birthplace of key nucleotide-modification and LNP discoveries, with strict ATMP regulation.

BioNTech/CureVac phenomenon, EMA ATMP regulation

• BioNTech (Mainz): Comirnaty (with Pfizer) + onco-pipeline; modular BioNTainer plants.
• CureVac: oldest mRNA-stabilisation patent portfolio (GC optimisation, with GSK).
• EMA ATMP: strict validation of dsRNA clearance and LNP-size stability under GMP.

05Leading companies and research institutes

06Tech stack and innovations

The stack rests on cell-free synthesis, microfluidics and deep purification.

1. IVT synthesis (In Vitro Transcription):
   • T7 polymerase at 37°C, Mg^2+ cofactor; yield 5–10 g RNA/L.
   • full UTP→m1ΨTP replacement to bypass RIG-I/MDA5.
2. Microfluidic LNP assembly (Microfluidic LNP Assembly):
   • mixing lipids in ethanol with mRNA at pH 4.0; ethanol dilution triggers self-assembly.
3. Deep RNA purification (Deep RNA Purification):
   • RP-HPLC/HIC to remove dsRNA that drives interferon response.

07Value chains and production pipelines

Industrial pipeline of mRNA-LNP production (GMP)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. DNA template (linear)  │ ───> │ 2. IVT mRNA synthesis     │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. LNP assembly (microfl.)│ <─── │ 3. mRNA purification (HPLC)│
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. TFF (ethanol removal)  │ ───> │ 6. Fill & lyophilisation  │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: DNA template

Plasmid DNA (T7 promoter + poly-A 100–120 nt) is produced in E. coli and linearised with restriction enzymes.

Stage 2: IVT synthesis

The reactor is loaded with template, T7 polymerase, CleanCap and NTPs (UTP→m1ΨTP); 37°C, 2–4 h; DNase then removes the template.

Stage 3: mRNA purification

Ultrafiltration + RP-HPLC remove dsRNA; mRNA is transferred to pH 4.0 buffer and frozen at -80°C.

Stage 4: LNP assembly

Lipids in ethanol and mRNA at pH 4.0 are mixed in a microfluidic chip; the ionizable lipid binds the mRNA.

Stage 5: TFF

Tangential-flow filtration (100–300 kDa) removes ethanol and shifts the buffer to pH 7.4.

Stage 6: Fill & lyophilisation

Sterile 0.22 µm filtration, aseptic filling under nitrogen; lyophilisation with sucrose/trehalose; storage at -20…-80°C.